The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy.
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
COVID-19
/ epidemiology
Cohort Studies
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Incidence
Italy
/ epidemiology
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
Pregnancy Trimester, First
Prevalence
SARS-CoV-2
/ immunology
COVID-19
SARS-CoV-2
first trimester
pregnancy
seroprevalence
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
20
06
2020
revised:
01
07
2020
accepted:
02
07
2020
pubmed:
8
7
2020
medline:
10
3
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Congenitally- or perinatally-acquired viral infections can be harmful to the fetus but data are limited about prevalence and outcomes of coronavirus disease 2019 (COVID-19) disease during the first trimester of pregnancy. We report epidemiologic data from a study investigating a cohort of women who became pregnant just before or during the COVID-19 pandemic. We recruited 138 consecutive pregnant women attending for first trimester screening (11-13 weeks of gestation) at Sant'Anna Hospital, Turin, Piedmont, Italy, during the plateau and the falling phase of the COVID-19 epidemic curve. Patients were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin M/immunoglobulin G antibody levels and SARS-CoV-2 detection in sera and nasopharyngeal swab samples. COVID-19 cumulative incidence during the first trimester was of 10.1% with high prevalence of asymptomatic patients (42.8%). Similar to the course of the disease in non pregnant adults, 80% to 90% of infections were not severe.The prevalence of reported symptoms was four-fold higher in SARS-CoV-2 positive patients (57%) than in those negative (13%) (P < .001), suggesting that direct self-testing should open doors to confirmatory testing for COVID-19. Our findings support the need for COVID-19 screening in early pregnancy in epidemic areas to plan materno-fetal health surveillance programs.
Identifiants
pubmed: 32633869
doi: 10.1002/jmv.26267
pmc: PMC7361535
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
537-540Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
Am J Obstet Gynecol. 2020 Jul;223(1):111.e1-111.e14
pubmed: 32335053
Int J Gynaecol Obstet. 2020 Jul;150(1):53-57
pubmed: 32350871
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
J Med Virol. 2020 Sep;92(9):1371-1372
pubmed: 32181904
J Med Virol. 2020 Oct;92(10):1718-1720
pubmed: 32248565
J Med Virol. 2021 Jan;93(1):537-540
pubmed: 32633869
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Am J Obstet Gynecol. 2020 Oct;223(4):612
pubmed: 32531218
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Eur J Obstet Gynecol Reprod Biol. 2020 Jun;249:98-99
pubmed: 32327266
N Engl J Med. 2020 May 28;382(22):2163-2164
pubmed: 32283004
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Eur J Obstet Gynecol Reprod Biol. 2020 Jul;250:246-249
pubmed: 32418711
BJOG. 2020 Aug;127(9):1116-1121
pubmed: 32339382
Am J Obstet Gynecol MFM. 2020 May;2(2):100118
pubmed: 32292903
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
J Med Virol. 2020 Sep;92(9):1556-1561
pubmed: 32222119